Dose

Phase 3Small molecule

UUnited States Naval Medical Center, San Diego

Dose is one of 71 small molecule programs targeting Migraine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

Eosinophilic EsophagitisActive, not recruiting

Safety IssuesEnrolling by invitation

MigrainePhase 3

Active, not recruiting

Eosinophilic EsophagitisPreclinical

Active, not recruiting

Safety IssuesPhase 1

Enrolling by invitation

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Dose

UUnited States Naval Medical Center, San Diego

Phase 3

1 2

Vyepti

Lundbeck

Preclinical

12 3

Savella

AbbVie

Preclinical

2 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 5

Botox

RRevance Therapeutics, Inc.

Preclinical

9 6

Adempas

Bayer

Preclinical

1 7

Nitrostat

VViatris Specialty LLC

Preclinical

2 8

Pristiq

PPrism Pharmaceuticals

Preclinical

1 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Botulinum Toxin a

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Active, not recruiting

Eosinophilic Esophagitis

NCT05309590

Clinical

Trials by Indication[1]

Migraine1 trial

Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?

Terminated·UUnited States Naval Medical Center, San Diego·Phase 3·NCT04349176·35 enrolled

Eosinophilic Esophagitis1 trial

Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children

Active, not recruiting·—··NCT05309590·50 enrolled

Safety Issues1 trial

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ETD-001 Gel in Healthy Chinese Subjects

Enrolling by invitation·EEtern Therapeutics Wuxi Limited·Phase 1·NCT07674862·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — United States Naval Medical Center, San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUnited States Naval Medical Center, San Diego

Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Migraine1 trial

Eosinophilic Esophagitis1 trial

Safety Issues1 trial

References

Drug Info

Quick Facts

Related News